Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Net Cash Flow (2016 - 2025)

Aptevo Therapeutics' Net Cash Flow history spans 11 years, with the latest figure at $11.7 million for Q3 2025.

  • For Q3 2025, Net Cash Flow rose 4114.78% year-over-year to $11.7 million; the TTM value through Sep 2025 reached $13.3 million, up 217.21%, while the annual FY2024 figure was -$8.2 million, 42.88% down from the prior year.
  • Net Cash Flow for Q3 2025 was $11.7 million at Aptevo Therapeutics, up from $7.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $16.2 million in Q1 2021 and bottomed at -$10.1 million in Q1 2022.
  • The 5-year median for Net Cash Flow is -$2.1 million (2024), against an average of -$1.1 million.
  • The largest annual shift saw Net Cash Flow tumbled 3840.68% in 2023 before it soared 4114.78% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$7.1 million in 2021, then surged by 100.83% to $59000.0 in 2022, then crashed by 3840.68% to -$2.2 million in 2023, then soared by 142.37% to $935000.0 in 2024, then skyrocketed by 1149.52% to $11.7 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Net Cash Flow are $11.7 million (Q3 2025), $7.3 million (Q2 2025), and -$6.6 million (Q1 2025).